The inspector perspective on TMF review
Understand how FDA, EMA, and other inspectors approach TMF review, what they look for first, and how TMF quality influences overall inspection outcomes.
The letter that changes everything
Dr. Rebecca Hwang opens her email at 7:42 AM on a Tuesday morning in late February and feels her pulse quicken. The subject line reads: "FDA Bioresearch Monitoring Program Inspection Notification - ELEVATE-HF Trial."
The letter is brief and direct. The FDA Division of Bioresearch Monitoring has scheduled an inspection of Lakewood Regional Medical Center in Minneapolis, Minnesota, for March 18-20. The inspection will focus on the site's conduct of the ELEVATE-HF cardiovascular outcomes trial. FDA Inspector Dr. Patricia Moran will arrive at 9:00 AM on the first day.